Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Sends Precautionary Notice To Doctors For Diabetes Drugs Containing Rosiglitazone

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Food and Drug Administration issued its second precautionary notice to doctors, calling for caution in prescribing diabetes drugs containing rosiglitazone, including GlaxoSmithKline's Avandia and Avandaryl, Sanofi Aventis' Amavan, and local Korean Yuhan Corp.'s generic rosiglitazone
Advertisement

Related Content

Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
Advertisement
UsernamePublicRestriction

Register

SC074487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel